Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
Nature Medicine,
Год журнала:
2024,
Номер
30(10), С. 2849 - 2856
Опубликована: Июнь 24, 2024
Abstract
People
with
type
2
diabetes
and
chronic
kidney
disease
have
a
high
risk
for
failure
cardiovascular
(CV)
complications.
Glucagon-like
peptide-1
receptor
agonists
sodium-glucose
cotransporter-2
inhibitors
(SGLT2i)
independently
reduce
CV
events.
The
effect
of
combining
both
is
unclear.
FLOW
trial
participants
were
stratified
by
baseline
SGLT2i
use
(
N
=
550)
or
no
2,983)
randomized
to
semaglutide/placebo.
primary
outcome
was
composite
failure,
≥50%
estimated
glomerular
filtration
rate
reduction,
death
death.
the
24%
lower
in
all
treated
semaglutide
versus
placebo
(95%
confidence
interval:
34%,
12%).
occurred
41/277
(semaglutide)
38/273
(placebo)
on
at
(hazard
ratio
1.07;
95%
0.69,
1.67;
P
0.755)
290/1,490
372/1,493
not
taking
0.73;
0.63,
0.85;
<
0.001;
interaction
0.109).
Three
confirmatory
secondary
outcomes
predefined.
Treatment
differences
favoring
total
slope
(ml
min
−1
/1.73
m
/year)
0.75
(−0.01,
1.5)
subgroup
1.25
(0.91,
1.58)
non-SGLT2i
subgroup,
0.237.
Semaglutide
benefits
major
events
all-cause
similar
regardless
0.741
0.901,
respectively).
reducing
consistent
with/without
use;
power
limited
detect
smaller
but
clinically
relevant
effects.
ClinicalTrials.gov
identifier:
NCT03819153
.
Язык: Английский
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
Drugs,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 28, 2024
Язык: Английский
6. CARDIO-RENAL PROTECTION IN TYPE 2 DIABETES
Diabetes Research and Clinical Practice,
Год журнала:
2025,
Номер
unknown, С. 112150 - 112150
Опубликована: Апрель 1, 2025
Язык: Английский
Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies
Diabetes & Metabolism,
Год журнала:
2024,
Номер
unknown, С. 101594 - 101594
Опубликована: Ноя. 1, 2024
Язык: Английский
Correction to: Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies
Cardiovascular Diabetology,
Год журнала:
2024,
Номер
23(1)
Опубликована: Июнь 1, 2024
regarding
the
CV
effects
of
oral
semaglutide
in
individuals
with
type
2
diabetes
and
established
ASCVD
and/or
CKD
[46]"
instead
"The
SOUL
study
demonstrated
non-inferiority
to
placebo
terms
mortality
outcomes
[46]".The
updated
Acknowledgements
statement
should
read,
"We
would
like
thank
BioQuest
Solutions
Pvt.Ltd
for
providing
medical
Язык: Английский
Evaluating the effectiveness and safety of empagliflozin versus liraglutide in managing diabetic dyslipidemia: An observational study
Motakatla Usha Rani,
Chitra Karuppiah,
Penupothu Sree Nagamani
и другие.
Asian Journal of Medical Sciences,
Год журнала:
2024,
Номер
15(7), С. 137 - 141
Опубликована: Июль 1, 2024
Background:
Diabetic
dyslipidemia
poses
a
significant
risk
factor
for
cardiovascular
complications
in
patients
with
diabetes
mellitus.
Empagliflozin
and
liraglutide
are
two
commonly
used
medications
management,
yet
their
comparative
efficacy
safety
treating
diabetic
remain
under-explored.
Aims
Objectives:
This
study
aimed
to
assess
the
effectiveness
of
versus
managing
dyslipidemia.
Materials
Methods:
The
enrolled
100
participants
dyslipidemia,
divided
equally
into
empagliflozin
treatment
groups.
Baseline
characteristics,
including
age,
gender
distribution,
ethnicity,
duration
diabetes,
were
assessed
compared
between
Lipid
profiles,
encompassing
total
cholesterol,
low-density
lipoprotein
(LDL)
high-density
(HDL)
triglycerides,
evaluated
at
baseline
after
6
months
treatment.
Safety
outcomes,
such
as
occurrence
mild
gastrointestinal
symptoms,
hypoglycemia,
serious
adverse
events,
also
monitored.
Results:
Both
groups
exhibited
comparable
characteristics.
Following
treatment,
both
demonstrated
improvements
lipid
profiles.
Reductions
LDL
along
increases
HDL
observed
Moreover,
there
no
differences
events
groups,
indicating
similar
Conclusion:
provides
evidence
supporting
These
findings
highlight
potential
viable
therapeutic
options
Язык: Английский
Recent Advances Associated with Cardiometabolic Remodeling in Diabetes-induced Heart Failure
AJP Heart and Circulatory Physiology,
Год журнала:
2024,
Номер
327(6), С. H1327 - H1342
Опубликована: Окт. 25, 2024
Diabetes
mellitus
(DM)
is
characterized
by
chronic
hyperglycemia,
and
despite
intensive
glycemic
control,
the
risk
of
heart
failure
in
patients
with
diabetes
remains
high.
Diabetes-induced
(DHF)
presents
a
unique
metabolic
challenge,
driven
significant
alterations
cardiac
substrate
metabolism,
including
increased
reliance
on
fatty
acid
oxidation,
reduced
glucose
utilization,
impaired
mitochondrial
function.
These
lead
to
oxidative
stress,
lipotoxicity,
energy
deficits,
contributing
progression
failure.
Emerging
research
has
identified
novel
mechanisms
involved
remodeling
diabetic
hearts,
such
as
autophagy
dysregulation,
epigenetic
modifications,
polyamine
regulation,
branched-chain
amino
(BCAA)
metabolism.
processes
exacerbate
dysfunction
inflexibility,
further
impairing
Therapeutic
interventions
targeting
these
pathways—such
enhancing
modulating
optimizing
ketone
body
utilization—show
promise
restoring
homeostasis
improving
outcomes.
This
review
explores
key
molecular
driving
highlights
advanced
methodologies,
latest
therapeutic
strategies
for
mitigating
DHF.
Understanding
emerging
pathways
offers
new
opportunities
develop
targeted
therapies
that
address
root
causes
diabetes.
Язык: Английский
Hepatoprotective Benefits of SGLT-2 Inhibitors and GLP-1 Analogs
Journal of Diabetology,
Год журнала:
2024,
Номер
15(4), С. 458 - 459
Опубликована: Окт. 1, 2024
Язык: Английский
Comparative Efficacy and Safety of Cardio-Renoprotective Pharmacological Interventions in Chronic Kidney Disease: An Umbrella Review of Network Meta-Analyses and a Multicriteria Decision Analysis
Biomolecules,
Год журнала:
2024,
Номер
15(1), С. 39 - 39
Опубликована: Дек. 31, 2024
Sodium-glucose
co-transporter
2
inhibitors
(SGLT2i),
glucagon-like
peptide-1
receptor
agonists
(GLP1a),
and
non-steroidal
mineralocorticoid
antagonists
(ns-MRA)
are
promising
treatments
for
chronic
kidney
disease.
This
umbrella
review
of
network
meta-analyses
evaluated
their
effects
on
cardiovascular
outcomes,
disease
progression,
adverse
events,
using
the
TOPSIS
method
to
identify
optimal
intervention
based
P-scores.
A
total
19
44
randomized
controlled
trials
involving
86,150
patients
were
included.
Compared
placebo,
SGLT2i
associated
with
reduced
risks
events
[Hazard
ratio
(HR):
0.776,
95%
confidence
intervals
(CI):
0.727–0.998],
progression
(HR:
0.679,
CI:
0.629–0.733),
acute
injury
0.873,
0.773–0.907),
serious
0.881,
0.847–0.916).
GLP1a
ns-MRA
also
significant
reductions
in
kidney-specific
composite
outcomes.
Indirect
evidence
showed
that
demonstrated
a
lower
risk
compared
0.826,
0.716–0.952)
0.818,
0.673–0.995),
representing
best
across
all
endpoints.
In
conclusion,
while
SGLT2i,
GLP1a,
reduce
disease,
appears
provide
most
favorable
balance
efficacy
safety.
Язык: Английский
Evaluating the effectiveness and safety of empagliflozin versus liraglutide in managing diabetic dyslipidemia: An observational study
Motakatla Usha Rani,
Chitra Karuppiah,
Penupothu Sree Nagamani
и другие.
Asian Journal of Medical Sciences,
Год журнала:
2024,
Номер
15(7), С. 137 - 141
Опубликована: Июль 1, 2024
Background:
Diabetic
dyslipidemia
poses
a
significant
risk
factor
for
cardiovascular
complications
in
patients
with
diabetes
mellitus.
Empagliflozin
and
liraglutide
are
two
commonly
used
medications
management,
yet
their
comparative
efficacy
safety
treating
diabetic
remain
under-explored.
Aims
Objectives:
This
study
aimed
to
assess
the
effectiveness
of
versus
managing
dyslipidemia.
Materials
Methods:
The
enrolled
100
participants
dyslipidemia,
divided
equally
into
empagliflozin
treatment
groups.
Baseline
characteristics,
including
age,
gender
distribution,
ethnicity,
duration
diabetes,
were
assessed
compared
between
Lipid
profiles,
encompassing
total
cholesterol,
low-density
lipoprotein
(LDL)
high-density
(HDL)
triglycerides,
evaluated
at
baseline
after
6
months
treatment.
Safety
outcomes,
such
as
occurrence
mild
gastrointestinal
symptoms,
hypoglycemia,
serious
adverse
events,
also
monitored.
Results:
Both
groups
exhibited
comparable
characteristics.
Following
treatment,
both
demonstrated
improvements
lipid
profiles.
Reductions
LDL
along
increases
HDL
observed
Moreover,
there
no
differences
events
groups,
indicating
similar
Conclusion:
provides
evidence
supporting
These
findings
highlight
potential
viable
therapeutic
options
Язык: Английский